12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALKS 3831: Phase I data

A double-blind, placebo- and active-controlled Phase I trial in 106 healthy volunteers showed that subjects receiving once-daily oral ALKS 3831 had significantly less mean weight...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >